Form 4: AN2 Therapeutics Director Kabeer Aziz Reports Share Transactions

Director Kabeer Aziz reports acquisition and disposal of AN2 Therapeutics shares, including shares issued in lieu of cash compensation.

Summary

• Kabeer Aziz, a director of AN2 Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On April 10, 2025, Aziz acquired 9,705 shares of common stock at $0, issued in lieu of cash compensation under the company's non-employee director compensation policy.
• Aziz also disposed of 18,677 shares of common stock.
• Following these transactions, Aziz directly owns 18,677 shares.
• Aziz also indirectly owns 1,995,958 shares through Adjuvant Global Health Technology Fund, L.P. and 377,542 shares through Adjuvant Global Health Technology Fund DE, L.P.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The acquisition and disposal of shares offset each other.

Positives

• The acquisition of shares in lieu of cash compensation aligns the director's interests with those of the shareholders.

Negatives

• The disposal of 18,677 shares by the director could be perceived negatively by investors.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may react to the director's share disposal.

Key Dates

Keywords

Form 4, beneficial ownership, ANTX, AN2 Therapeutics, Kabeer Aziz, director, share transactions, Adjuvant Global Health Technology Fund